HLA-E Behcet
Description
The knowledge of the aetiology of Behçet disease (BD), an immune-mediated vasculitis, is limited. HLA-B, mainly HLA-B51, and HLA-A molecules are associated with disease, but the ultimate cause of this association remains obscure. There is evidence that NK cells participate in the etiopathology of BD. NK cells have activator and inhibitor surface receptors, like the KIR and the NKG2 families. Classical HLA-class I molecules (A, B and C) are keys in the activity control of the NK because they are KIR ligands. Additionally, most NKG2 receptors bind HLA-E, which presents only nonapeptides derived from the signal peptide of other class-I molecules. To investigate the role of the pair HLA-E/HLA-class I in BD, we analyzed the frequency of the HLA-derivated nonapeptide forms in a cohort of 466 Behcet Disease (BD)-unrelated patients who fulfilled the 1990 International Study Group classification criteria for BD and 444 unrelated healthy individuals included in the control group. All the subjects were Spanish European recruited from 17 Spanish hospitals across the country. Besides, we analyzed an HLA-E functional dimorphism in a subgroup of 272 patients and 273 controls.
Files
Steps to reproduce
HLA class I (A, B and C) genotypes obtained in previous works of our group. Briefly, we used a PCR-SSOP Luminex method (LABType SSO Class I A Locus Typing Test, LABType SSO Class I B Locus Typing Test and LABType SSO Class I C Locus Typing Test. One Lambda Inc., Canoga Park, CA) according to the manufacturer´s instructions. The results were read in a flow analyzer, LABScanTM100, to quantify the fluorescence intensity on the microspheres. We used the HLA fusion 2.0 software (One Lambda Inc) for the HLA-locus typing assignment. Genotyping of the rs1264457 (NM_005516.6:c.382A>G p.Arg128Gly correspond to mature HLA-E protein codon 107) by using a TaqMan® SNP Genotyping Assay (Applied Biosystems, Barcelona, Spain) in a LightCycler 480 (Roche, Barcelona, Spain).
Institutions
Categories
Funding
Instituto de Salud Carlos III
ISCIII PI16/01373
Instituto de Salud Carlos III
PI19/00605